2014-10-20T15:10:19-05:00 2013-12-31 274760605 KULLMAN SIEBERT LLC 1997 ANNAPOLIS EXCHANGE PKWY STE 51 ANNAPOLIS MD 214013275 990 2013-01-01 270486705 ALLIANCE FOR REGENERATIVE MEDICINE ALLI 2024192515 525 SECOND STREET NE WASHINGTON DC 20002 GEOFF MACKAY CHAIRMAN 2024192515 2014-08-21 true STEPHEN J KULLMAN CPA P00308157 4102669885 2014-08-21 2013 2015-11-30 17:44:51Z GEOFF MACKAY 525 SECOND STREET NE WASHINGTON DC 20002 1973895 false X WWW.ALLIANCERM.ORG X 2009 DC TO EDUCATE KEY POLICY MAKERS ABOUT THE POTENTIAL OF REGENERATIVE MEDICINE AND TO ADVOCATE FOR FAVORABLE PUBLIC POLICIES - FUNDING, REGULATORY, REIMBURSEMENT AND OTHERS AND TO FACILITATE ADVANCES IN THE FIELD 23 23 0 43 0 55750 176000 1560017 1797820 99 75 0 1615866 1973895 0 0 0 0 0 1470975 1817789 1470975 1817789 144891 156106 516489 689929 38172 55506 478317 634423 X TO EDUCATE KEY POLICY MAKERS ABOUT THE POTENTIAL OF REGENERATIVE MEDICINE AND TO ADVOCATE FOR FAVORABLE PUBLIC POLICIES - FUNDING, REGULATORY, REIMBURSEMENT AND OTHERS AND TO FACILITATE ADVANCES IN THE FIELD false false 526602 POLICY, ADVOCACY AND GOVERNMENT RELATIONS ACTIVITIES AND ACCOMPLISHMENTS INCLUDE, BUT ARE NOT LIMITED TO: A. GOVERNMENT RELATIONS: RMPA/STRATEGIC ASSESSMENT/NATIONAL STRATEGY; PATIENT ADVOCACY GROUP OUTREACH; LEGISLATIVE DAY AND FLY-IN ACTIVITIES; RM NATIONAL STRATEGY WORKSHOP; AFIRM REAUTHORIZATION/DEPARTMENT OF DEFENSE; PDUFA ADVOCACY SUPPORT. B. REGULATORY: INTERNATIONAL REGULATORY WORKSHOP - HARMONIZATION; FDA COMMUNICATIONS WHITE PAPER; MEETINGS WITH FDA/PARTICIPATION IN REGULATORY PROCESS/COMMENTS FILED; ARM FDA WORKSHOP; TASK FORCE ON ANIMAL MODELS; DEVELOPMENT OF REGULATORY MATRIX/ROADMAP TO ASSIST MEMBERS WITH REGULATORY DECISION MAKING. C. REIMBURSEMENT: PHARMACO-ECONOMIC STUDIES IN KEY THERAPEUTIC AREAS; WHITE PAPER ON PRODUCTS IN DEVELOPMENT - UNIQUE REIMBURSEMENT ISSUES; FUNDING TO SUPPORT PROJECTS FROM CMS, AHRQ, AND PCORI MEETINGS; PRIVATE INSURERS - WORKSHOP SERIES; CATALOGING AND IDENTIFYING CLINICAL KOLS BY DISEASE AREA. 827517 COMMUNICATIONS, CAPITAL FORMATION, OPERATIONS ACTIVITIES AND ACCOMPLISHMENTS INCLUDE, BUT ARE NOT LIMITED TO: A. COMMUNICATIONS: DEVELOPMENT OF ANNUAL INDUSTRY REPORT; WEBSITE UPGRADE - WITH KEY MEMBER INTERACTION FEATURES; WEBSITE MAINTENANCE; PUBLICATION OF BI-WEEKLY NEWSLETTER FOR RM COMMUNITY; SOCIAL MEDIA STRATEGY FOR POLITICAL AGENDA AND INVESTOR OUTREACH; PUBLIC RELATIONS AND MARKETING; CULTIVATION OF RELATIONSHIPS WITH PRESS AND MEDIA; DEVELOPMENT OF MATERIALS TO EDUCATE THE PUBLIC ABOUT RM. B. CAPITAL FORMATION: NEW YORK INVESTOR MEETING; VENTURE/DIRECTED PHILANTHROPY FUND; FEDERAL FUNDING OPPORTUNITIES FOR RM IDENTIFICATION PROJECT; DEVELOPMENT OF MASTER CONTACT LIST OF INVESTORS AND KEY PHARMA CONTACTS FOR MEMBERS. C. OPERATIONS AND GOVERNANCE: UPDATE OF ALL MEMBERSHIP MATERIALS AND DEVELOPMENT OF NEW ONES; CONFERENCES AND EVENTS INCLUDING: STEM CELL MEETING ON THE MESA, CLINICAL OUTLOOKS IN REGENERATIVE, RM STATE OF THE INDUSTRY ADDRESS, ARM ANNUAL DINNER ADVANCED THERAPIES SUMMIT IN EUROPE; COSTS ASSOCIATED WITH BOARD, EXECUTIVE COMMITTEE AND STRATEGIC PLANNING MEETINGS; LAUNCH OF EUROPEAN CHAPTER - ALLIANCE FOR ADVANCED THERAPIES. 150458 SCIENCE AND TECHNOLOGY ACTIVITIES AND ACCOMPLISHMENTS INCLUDE, BUT ARE NOT LIMITED TO: A. POTENCY PROJECT; DEVELOP ON-LINE DATABASE AND DATA COLLECTION SYSTEM FOR MEMBERS TO ACCESS AND STAFF TO MAINTAIN POTENCY PROJECT INFORMATION; DEVELOPMENT OF ECONOMIC/BUSINESS MODEL TO MAINTAIN DATA RESOURCES AND REFERENCE STANDARD CELL BANK; WHITE PAPER ON NEXT INITIATIVE - STABILITY, GENOMIC MARKERS AND QC; COORDINATION WITH OTHER KEY STANDARDS ORGANIZATIONS - ISCT, ISSCR, ASTM, USP, NIST. OTHER ACTIVITIES INCLUDING: DISCUSSIONS WITH HEALTH CARE PROVIDERS TO ENSURE ADEQUATE COVERAGE OF REGENERATIVE MEDICINE PRODUCTS; PRESENTING INFORMATION AT PUBLIC MEETINGS CONVENED BY FDA AND NIH; PUBLISHING A BI- WEEKLY NEWSLETTER ENTITLED REGENERATIVE MEDICINE FORUM ALONG WITH THE GENETICS POLICY INSTITUTE; HELD ANNUAL MEETING IN WASHINGTON, D.C. 1504577 false true false true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false true 7 0 0 false false false false true true false X 23 23 false false false false false false false true true false false false true true true false false false false false X X THOMAS J DULA 7038551301 525 SECOND STREET NE WASHINGTON DC 20002 X GIL VAN BOKKELEN DIRECTOR EX- 10.00 X 0 0 0 ED FIELD TREASURER 10.00 X X 0 0 0 DR ANTHONY ATALA DIRECTOR 10.00 X 0 0 0 DEAN TOZER DIRECTOR 10.00 X 0 0 0 MATTHEW VINCENT DIRECTOR 10.00 X 0 0 0 DOUG DOERFLER DIRECTOR 10.00 X 0 0 0 ROBERT SHAW DIRECTOR 10.00 X 0 0 0 MARTIN MCGLYNN SECRETARY 10.00 X X 0 0 0 KEITH MURPHY VICE CHAIR 10.00 X X 0 0 0 ROBERT PRETI DIRECTOR 10.00 X 0 0 0 DEVYN SMITH DIRECTOR 10.00 X 0 0 0 MATTHIAS STEGER DIRECTOR 10.00 X 0 0 0 BERNARD SIEGEL DIRECTOR 10.00 X 0 0 0 SUSAN SOLOMON DIRECTOR 10.00 X 0 0 0 ALAN TROUNSON DIRECTOR 10.00 X 0 0 0 CHRIS CALHOUN DIRECTOR 10.00 X 0 0 0 LEANNA CARON DIRECTOR 10.00 X 0 0 0 AMY COMSTOCK RICK DIRECTOR 10.00 X 0 0 0 SILIVIU ITESCU DIRECTOR 10.00 X 0 0 0 ED LANPHIER DIRECTOR 10.00 X 0 0 0 GEOFF MACKAY CHAIRMAN 10.00 X X 0 0 0 JAY SIEGEL DIRECTOR 10.00 X 0 0 0 DAVID SMITH DIRECTOR 10.00 X 0 0 0 CLAUDIA ZYLBERBERG DIRECTOR 10.00 X 0 0 0 false false false ADJUVANT PARTNERS LLC 722 DULANEY VALLEY ROAD SUITE 262 TOWSON MD 21204 MANAGEMENT ADV 300000 HOLLAND AND KNIGHT LLP 800 17TH STREET NW SUITE 1100 WASHINGTON DC 20006 LEGAL 300000 2 176000 176000 MEMBERSHIP DUES 1133050 1133050 STEM CELL CONFERENCE 495337 495337 REGENMED INVESTOR MEETING 121427 121427 ANNUAL MEETING 48006 48006 1797820 75 75 1973895 1797820 75 X 300000 150000 150000 90000 90000 34800 34800 210000 210000 291694 291694 76793 76793 15743 15743 7824 7824 27502 27502 42518 41968 550 525787 525787 MEMBERSHIP SUPPORT 195128 195128 1817789 1504577 313212 0 42812 233626 100052 140106 345913 269775 2712 2712 18710 25000 25000 516489 689929 38172 55506 38172 55506 X 478317 634423 478317 634423 516489 689929 156106 X false false false RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false 1133050 210000 210000 357615 -147615 ADJUVANT PARTNERS LLC FORMER DIRECTOR 300000 MANAGEMENT FEES false ADJUVANT PARTNERS LLC FORMER DIRECTOR 96553 CONFERENCE PLANNING false ADJUVANT PARTNERS LLC FORMER DIRECTOR 148283 EVENT EXPENSES false ADJUVANT PARTNERS LLC FORMER DIRECTOR 88876 ADMIN SUPPORT false ADJUVANT PARTNERS LLC FORMER DIRECTOR 117376 OTHER OPERATING EXP false SCHEDULE L, PART V SCHEDULE L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: ADJUVANT PARTNERS LLC (B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: EDMUND RUFFIN (FORMER DIRECTOR) OWNS 100% OF ADJUVANT PARTNERS LLC (D) DESCRIPTION OF TRANSACTION: MANAGEMENT FEES, CONFERENCE PLANNING FEES, ADMINISTRATION SUPPORT, EVENT EXPENSES, AND OTHER OPERATING EXPENSES PAID TO ADJUVANT LLC. FORM 990, PAGE 2, PART III, LINE 4A C. REIMBURSEMENT: PHARMACO-ECONOMIC STUDIES IN KEY THERAPEUTIC AREAS; WHITE PAPER ON PRODUCTS IN DEVELOPMENT - UNIQUE REIMBURSEMENT ISSUES; FUNDING TO SUPPORT PROJECTS FROM CMS, AHRQ, AND PCORI MEETINGS; PRIVATE INSURERS - WORKSHOP SERIES; CATALOGING AND IDENTIFYING CLINICAL KOLS BY DISEASE AREA. FORM 990, PAGE 2, PART III, LINE 4B CONTACTS FOR MEMBERS. C. OPERATIONS AND GOVERNANCE: UPDATE OF ALL MEMBERSHIP MATERIALS AND DEVELOPMENT OF NEW ONES; CONFERENCES AND EVENTS INCLUDING: STEM CELL MEETING ON THE MESA, CLINICAL OUTLOOKS IN REGENERATIVE, RM STATE OF THE INDUSTRY ADDRESS, ARM ANNUAL DINNER ADVANCED THERAPIES SUMMIT IN EUROPE; COSTS ASSOCIATED WITH BOARD, EXECUTIVE COMMITTEE AND STRATEGIC PLANNING MEETINGS; LAUNCH OF EUROPEAN CHAPTER - ALLIANCE FOR ADVANCED THERAPIES. FORM 990, PAGE 2, PART III, LINE 4D OTHER ACTIVITIES INCLUDING: DISCUSSIONS WITH HEALTH CARE PROVIDERS TO ENSURE ADEQUATE COVERAGE OF REGENERATIVE MEDICINE PRODUCTS; PRESENTING INFORMATION AT PUBLIC MEETINGS CONVENED BY FDA AND NIH; PUBLISHING A BI- WEEKLY NEWSLETTER ENTITLED REGENERATIVE MEDICINE FORUM ALONG WITH THE GENETICS POLICY INSTITUTE; HELD ANNUAL MEETING IN WASHINGTON, D.C. FORM 990, PAGE 6, PART VI, LINE 11B THE TREASURER REVIEWS THE TAX RETURN ALONG WITH THE OTHER OFFICERS OF THE ORGANIZATION PRIOR TO FILING FORM 990, PAGE 6, PART VI, LINE 12C THE CONFLICT OF INTEREST POLICY COVERS ANY DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS. DISCLOSURE IS TO DIRECTORS AND MEMBERS OF COMMITTEES WITH GOVERNING BOARD DELEGATED POWERS. DISCLOSURES ARE REVIEWED AND MAINTAINED BY THE REMAINING MEMBERS OF THE GOVERNING BOARD OR COMMITTEE. THE GOVERNING BOARD OR COMMITTEE REVIEWS EACH TRANSACTION TO COME BEFORE THE BOARD FOR POTENTIAL OR ACTUAL CONFLICTS OF INTEREST. IF POTENTIAL OR ACTUAL CONFLICTS (PAST, PRESENT OR FUTURE) ARE IDENTIFIED, THE CHAIRPERSON OF THE GOVERNING BOARD OR COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER EXERCISING DUE DILIGENCE, THE GOVERNING BOARD OR COMMITTEE SHALL DETERMINE WHETHER ARM CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. THE IDENTIFIED CONFLICTS OF INTEREST AND APPROPRIATE RECUSALS ARE DOCUMENTED IN THE MINUTES OF EACH BOARD OR COMMITTEE MEETING. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART IX, LINE 11G CONFERENCE & EVENT PLANNING 180,005 0 0 COMMUNICATIONS CONSULTING 7,743 0 0 ANNUAL REPORT DATA 6,764 0 0 MEMBERSHIP MATERIALS 106 0 0 FDA-EMA WORKSHOPS 3,000 0 0 REIMBURSMENT WHITE PAPERS 20,400 0 0 COMMITTEE MEETINGS 1,956 0 0 ISCT JOINT WHITE PAPER PROJ 4,680 0 0 STANDARDS WORKSHOP 5,000 0 0 TEBC CONSULTING 54,000 0 0 TEBC PROJECTS 8,040 0 0